EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J‐ TAIL ‐2

Yasushi Goto iD, Makoto Nishio iD, Kadoaki Ohashi iD, Atsushi Osoegawa, Eiki Kikuchi iD, Hideharu Kimura, Junichi Shimizu, Eisaku Miyauchi iD, Hiroshige Yoshioka iD, Ichiro Yoshino, Toshihiro Misumi, Yasutaka Watanabe und 8 weitere

Cancer Science · 2026

DOI: 10.1111/cas.70375 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Science, 2026. Verfasst von Yasushi Goto und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Blood Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chugai Pharmaceutical Co., Ltd., Chugai Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

J‐TAIL‐2 evaluated the efficacy and safety of atezolizumab, an anti–programmed death‐ligand 1 (PD‐L1), plus chemotherapy in patients with non‐small cell lung cancer (NSCLC) and extensive‐stage small cell lung cancer (ES‐SCLC) in Japanese clinical practice, demonstrating comparable outcomes to those in the corresponding Phase 3 trials. Although PD‐L1 expression is predictive of atezolizumab efficacy in some settings, additional minimally invasive, blood‐based biomarkers are needed. This exploratory biomarker study included 359 J‐TAIL‐2 patients. The NSCLC cohort received atezolizumab combined with carboplatin and nab‐paclitaxel (CnP, n = 42), cisplatin/carboplatin and pemetrexed ( n = 72), or bevacizumab plus carboplatin and paclitaxel (bev + CP, n = 135). The ES‐SCLC cohort received atezolizumab plus carboplatin and etoposide ( n = 100). Approximately 560 cancer‐ or immune‐related proteins were evaluated using the Proximity Extension Assay from blood plasma collected at three timepoints: baseline, before the second atezolizumab dose, and at the onset of immune‐related adverse events (irAEs). Protein‐wise comparisons were made to evaluate significant changes ( P < 0.05 and > 0.5 log2 fold change) and linked to clinical outcomes reported in J‐TAIL‐2. IL‐6, MUC‐16, and KRT‐19 were associated with shorter progression‐free survival across multiple regimens. Granzyme A and B, immune activation markers, were elevated in responders who received atezolizumab + CnP and atezolizumab + bev + CP. High levels of baseline immune stimulation proteins were associated with irAEs across regimens. Protein expression changes were varied and regimen‐dependent in subgroup analyses including older patients and those with EGFR ‐mutant tumors. These data warrant further investigation across different cancer types and atezolizumab‐containing regimens to determine their relevance to efficacy and irAE occurrence of atezolizumab combination therapy. Trial Registration: ClinicalTrials.gov ID, NCT04501497 (J‐TAIL‐2) and NCT04818983 (biomarker study)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBlood ProteinsCarcinoma, Non-Small-Cell LungLung NeoplasmsSmall Cell Lung CarcinomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAlbuminsBevacizumabCarboplatinCisplatinEtoposidePaclitaxelPemetrexed

Stichwörter der Autor:innen

atezolizumabbiomarkernon‐small cell lung cancerplasma proteinsmall cell lung cancer

Substanzen

130-nm albumin-bound paclitaxelAlbuminsAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabBiomarkers, TumorBlood ProteinsCarboplatinCisplatinEtoposide

Autor:innen und Institutionen

  • Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
  • Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Yufu, Japan.
  • Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Japan.

ORCID-Profile: Yasushi Goto, Makoto Nishio, Kadoaki Ohashi, Eiki Kikuchi, Eisaku Miyauchi, Hiroshige Yoshioka, Nobuyuki Katakami, Akihiko Gemma

Förderung

  • Chugai Pharmaceutical Co., Ltd.
  • Chugai Pharmaceutical

Zitieren

APA

Goto, Y., Nishio, M., Ohashi, K., Osoegawa, A., Kikuchi, E., Kimura, H., Shimizu, J., Miyauchi, E., Yoshioka, H., Yoshino, I., Misumi, T., Watanabe, Y., Katakami, N., Kisohara, A., Yamaguchi, M., Kuroki, H., Sugimoto, M., Ashimura, H., Tanaka, M., & Gemma, A. (2026). Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J‐ TAIL ‐2. Cancer Science. https://doi.org/10.1111/cas.70375

Vancouver

Goto Y, Nishio M, Ohashi K, Osoegawa A, Kikuchi E, Kimura H, et al. Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J‐ TAIL ‐2. Cancer Science. 2026. doi:10.1111/cas.70375

BibTeX
@article{Goto2026,
  author = {Goto, Yasushi and Nishio, Makoto and Ohashi, Kadoaki and Osoegawa, Atsushi and Kikuchi, Eiki and Kimura, Hideharu and Shimizu, Junichi and Miyauchi, Eisaku and Yoshioka, Hiroshige and Yoshino, Ichiro and Misumi, Toshihiro and Watanabe, Yasutaka and Katakami, Nobuyuki and Kisohara, Akira and Yamaguchi, Masafumi and Kuroki, Hirotaka and Sugimoto, Masamichi and Ashimura, Hisao and Tanaka, Misa and Gemma, Akihiko},
  title = {Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J‐ TAIL ‐2},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70375}
}
Kostenlos starten →